文献速递帕金森病与运动障碍

全身麻醉与局部麻醉在帕金森病微电极记录引导脑深部电刺激术中的比较:GALAXY随机临床试验

General Anesthesia vs Local Anesthesia in Microelectrode Recording-Guided Deep-Brain Stimulation for Parkinson Disease: The GALAXY Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2021-01-01

GALAXY单中心前瞻性随机开放标签盲终点试验纳入110例晚期帕金森病患者,比较全麻下睡眠状态与局麻下清醒状态双侧丘脑底核脑深部电刺激术(DBS)的认知、情绪和行为不良反应复合评分。6个月随访时两组复合评分不良反应比例分别为22%和29%(OR 0.7,95%CI 0.3-1.7),运动症状改善无差异,睡眠手术患者负担更轻且手术时间短26分钟。

要点

  • 睡眠状态与清醒状态DBS在认知、情绪和行为不良反应复合评分上无显著差异。
  • 两组停药状态下MDS-UPDRS运动检查评分改善无差异(平均差-2.0,95%CI -8.1至4.2)。
  • 睡眠手术患者体验负担更轻,手术时间较清醒手术短26分钟。

核心结论

  • 睡眠状态与清醒状态丘脑底核DBS在认知、情绪和行为不良反应主要结局上无差异。

研究设计与样本

  • 单中心前瞻性随机开放标签盲终点临床试验,2015年5月至2019年3月转诊的187例帕金森病患者中随机110例。
  • 随机分为清醒局麻组(n=56,平均年龄60.0岁,男性40例)和睡眠全麻组(n=54,平均年龄61.3岁,男性38例)。
  • 两组均采用框架式术中微电极记录技术优化DBS电极最终靶点放置,主要结局随访在DBS术后6个月进行。

主要发现

  • 6个月随访时复合评分显示认知、情绪和行为不良反应比例清醒组为15/52(29%),睡眠组为11/51(22%),OR 0.7(95%CI 0.3-1.7)。
  • 停药状态下MDS-UPDRS运动检查评分改善清醒组平均-27.3分(SD 17.5),睡眠组平均-25.3分(SD 14.3),平均差-2.0(95%CI -8.1至4.2)。
  • 睡眠手术患者体验负担更轻,手术时间较清醒手术短26分钟。

临床怎么用

  • 对于接受框架式微电极记录引导双侧丘脑底核DBS的晚期帕金森病患者,睡眠全麻与清醒局麻在认知情绪行为不良反应和运动改善上无显著差异。
  • 睡眠手术可减轻患者手术负担并缩短手术时间,可作为清醒手术的替代选择。

局限性

  • 本研究仅限于框架式微电极引导手术,结论不能直接推广至新型睡眠DBS技术。
  • 单中心设计可能限制结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unknown if there is a difference in outcome in asleep vs awake deep brain stimulation (DBS) of the subthalamic nucleus for advanced Parkinson disease. OBJECTIVE: To determine the difference in adverse effects concerning cognition, mood, and behavior between awake and asleep DBS favoring the asleep arm of the study. DESIGN, SETTING, AND PARTICIPANTS: This study was a single-center prospective randomized open-label blinded end point clinical trial. A total of 187 persons with Parkinson disease were referred for DBS between May 2015 to March 2019. Analysis took place from January 2016 to January 2020. The primary outcome follow-up visit was conducted 6 months after DBS. INTERVENTIONS: Bilateral subthalamic nucleus DBS was performed while the patient was asleep (under general anesthesia) in 1 study arm and awake in the other study arm. Both arms of the study used a frame-based intraoperative microelectrode recording technique to refine final target placement of the DBS lead. MAIN OUTCOMES AND MEASURES: The primary outcome variable was the between-group difference in cognitive, mood, and behavioral adverse effects as measured by a composite score. The secondary outcomes included the Movement Disorders Society Unified Parkinson's Disease Rating Scale, the patient assessment of surgical burden and operative time. RESULTS: A total of 110 patients were randomized to awake (local anesthesia; n = 56; mean [SD] age, 60.0 (7.4) years; 40 [71%] male) or to asleep (general anesthesia; n = 54; mean [SD] age, 61.3 [7.9] years; 38 [70%] male) DBS surgery. The 6-month follow-up visit was completed by 103 participants. The proportion of patients with adverse cognitive, mood, and behavioral effects on the composite score was 15 of 52 (29%) after awake and 11 of 51 (22%) after asleep DBS (odds ratio, 0.7 [95% CI, 0.3-1.7]). There was no difference in improvement in the off-medication Movement Disorders Society Unified Parkinson's Disease Rating Scale Motor Examination scores between groups (awake group: mean [SD], -27.3 [17.5] points; asleep group: mean [SD], -25.3 [14.3] points; mean difference, -2.0 [95% CI, -8.1 to 4.2]). Asleep surgery was experienced as less burdensome by patients and was 26 minutes shorter than awake surgery. CONCLUSIONS AND RELEVANCE: There was no difference in the primary outcome of asleep vs awake DBS. Future large randomized clinical trials should examine some of the newer asleep based DBS technologies because this study was limited to frame-based microelectrode-guided procedures. TRIAL REGISTRATION: trialregister.nl Identifier: NTR5809.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Holewijn RA, Verbaan D, van den Munckhof PM, et al. General Anesthesia vs Local Anesthesia in Microelectrode Recording-Guided Deep-Brain Stimulation for Parkinson Disease: The GALAXY Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 34491267. doi:10.1001/jamaneurol.2021.2979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。